{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:44:03Z","timestamp":1780443843350,"version":"3.54.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172034, 82373101"],"award-info":[{"award-number":["82172034, 82373101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant immunochemotherapy (nICT) improves outcomes in esophageal squamous cell carcinoma (ESCC); however, patient response heterogeneity limits its clinical benefit. The aim of this study was to investigate the predictive value of the systemic immune-inflammation index and prognostic nutritional index score (SII-PNI score), which is jointly constructed from the systemic immune-inflammation index (SII) and prognostic nutritional index (PNI), for pathological complete response (pCR) and survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included patients with stage II to IV ESCC who received nICT therapy at Wuhan Union Hospital (WHUH), Fujian Cancer Hospital (FJCH), and 900th Hospital of the Joint Service Support Force of the People\u2019s Liberation Army of China (900th Hospital). The predictive performance of SII-PNI score was validated using receiver operating characteristic (ROC) curves. Multivariate logistic regression confirmed SII-PNI score as an independent predictor of pCR. Additionally, Cox regression model and Kaplan-Meier survival curves were employed to analyze disease-free Survival (DFS) and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 345 patients were included, stratified into 0-score (n = 70), 1-score (n = 149), and 2-score (n = 126) groups. The combined cohort (Combined from FJCH cohort, WHUH cohort, 900th Hospital cohort) area under the ROC curve (AUC) revealed that SII-PNI score (AUC\u00a0=\u00a00.803) outperformed SII (AUC\u00a0=\u00a00.679, DeLong\u2019s test\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001) and PNI (AUC\u00a0=\u00a00.667, DeLong\u2019s test\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001) in predicting pCR. Compared with 0-score patients, those with 1-score (odds ratio [OR] = 0.159, 95% confidence interval [CI]:0.080-0.319,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001) and 2-score (OR\u00a0=\u00a00.025, 95% CI:0.009-0.073,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001) had significantly lower pCR rates. The 2-score group showed had shorter of DFS (hazard ratio [HR] = 2.487, 95% CI:1.414-4.374,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.002) and OS (HR\u00a0=\u00a04.473, 95% CI:2.138-9.357,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001) versus the 0-score group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrated for the first time that the SII-PNI score can be used as an independent predictor of pCR in patients with ESCC treated with nICT and has prognostic stratification value. This suggests that it has the potential to be a pre-treatment assessment tool for evaluating treatment response and prognosis before nICT treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1663268","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:17:21Z","timestamp":1763619441000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The crossroads of inflammation and nutrition: predicting neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Guisheng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingxin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqian","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanji","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17048","DOI":"10.1038\/nrdp.2017.48","article-title":"Oesophageal cancer","volume":"3","author":"Smyth","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4161\/cbt.8.1.7090","article-title":"Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers","volume":"8","author":"Kashyap","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321600","article-title":"Global burden of oesophageal and gastric cancer by histology and subsite in 2018","volume":"69","author":"Arnold","year":"2020","journal-title":"Gut"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13045-020-00981-4","article-title":"Burden, trends, and risk factors of esophageal cancer in China from 1990 to 2017: an up-to-date overview and comparison with those in Japan and South Korea","volume":"13","author":"Yang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004291","article-title":"Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03064-w","article-title":"Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial","volume":"30","author":"Qin","year":"2024","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.7118","article-title":"Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102","volume":"25","author":"Bedenne","year":"2007","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.06.041","article-title":"Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy","volume":"81","author":"Park","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5291-3","article-title":"Using the comprehensive complication index to assess the impact of neoadjuvant chemoradiotherapy on complication severity after esophagectomy for cancer","volume":"23","author":"Nederlof","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005830","article-title":"Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial","volume":"11","author":"Chen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1550003","article-title":"Tumor-infiltrating immune cells state-implications for various breast cancer subtypes","volume":"16","author":"Xu","year":"2025","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12967-022-03252-7","article-title":"Combining serum inflammation indexes at baseline and post treatment could predict pathological efficacy to anti\u2212PD\u22121 combined with neoadjuvant chemotherapy in esophageal squamous cell carcinoma","volume":"20","author":"Zhang","year":"2022","journal-title":"J Transl Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7150\/jca.25691","article-title":"Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis","volume":"9","author":"Yang","year":"2018","journal-title":"J Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/SLA.0000000000002985","article-title":"Prognostic nutritional index, tumor-infiltrating lymphocytes, and prognosis in patients with esophageal cancer","volume":"271","author":"Okadome","year":"2020","journal-title":"Ann Surg"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S190006","article-title":"Clinical significance of systemic immune-inflammation index (SII) and C-reactive protein-to-albumin ratio (CAR) in patients with esophageal cancer: a meta-analysis","volume":"11","author":"Zhang","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"110459","DOI":"10.1016\/j.intimp.2023.110459","article-title":"Comprehensive nutritional index predicts clinical outcomes for esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy combined with chemotherapy","volume":"121","author":"Feng","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0512-0","article-title":"Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups","volume":"20","author":"Andrews","year":"2019","journal-title":"Nat Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"100907","DOI":"10.1016\/j.drup.2022.100907","article-title":"Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade","volume":"66","author":"Pang","year":"2023","journal-title":"Drug Resist Update"},{"key":"B22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12943-021-01317-7","article-title":"Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades","volume":"20","author":"Li","year":"2021","journal-title":"Mol Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.970534","article-title":"Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching","volume":"13","author":"Jing","year":"2022","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-07147-0","article-title":"The prognostic value of a pathologic complete response after neoadjuvant therapy for digestive cancer: systematic review and meta-analysis of 21 studies","volume":"26","author":"Wan","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189294","article-title":"Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis","volume":"13","author":"Li","year":"2018","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"18258","DOI":"10.1038\/s41598-025-02454-5","article-title":"Prognostic value of immunotrophic inflammatory markers in ESCC undergoing chemoradiotherapy combined with immunotherapy","volume":"15","author":"Li","year":"2025","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","first-page":"27914","DOI":"10.1038\/s41598-025-11590-x","article-title":"Predicting pathological response of resectable esophageal squamous cell carcinoma to neoadjuvant anti-PD-1 with chemotherapy using serum inflammation indexes","volume":"15","author":"Song","year":"2025","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1186\/s12885-024-12771-z","article-title":"Combined systemic inflammatory immune index and prognostic nutrition index as chemosensitivity and prognostic markers for locally advanced gastric cancer receiving neoadjuvant chemotherapy: a retrospective study","volume":"24","author":"Ding","year":"2024","journal-title":"BMC Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S367964","article-title":"Pathologic complete response prediction to neoadjuvant immunotherapy combined with chemotherapy in resectable locally advanced esophageal squamous cell carcinoma: real-world evidence from integrative inflammatory and nutritional scores","volume":"15","author":"Feng","year":"2022","journal-title":"J Inflammation Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.1091601","article-title":"Predictive value of systemic immune-inflammation index for pathological complete response in patients receiving neoadjuvant immunochemotherapy for locally advanced esophageal cancer","volume":"9","author":"Han","year":"2022","journal-title":"Front Surg"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2022-0291","article-title":"Artificial intelligence in clinical applications for lung cancer: diagnosis, treatment and prognosis","volume":"60","author":"Pei","year":"2022","journal-title":"Clin Chem Lab Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/bjc.2011.189","article-title":"The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis","volume":"105","author":"Gooden","year":"2011","journal-title":"Br J Cancer"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1818488116","article-title":"Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRV\u03b41 and TCRV\u03b42 \u03b3\u03b4 T lymphocytes","volume":"116","author":"Pizzolato","year":"2019","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B34","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40425-019-0549-5","article-title":"Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines","volume":"7","author":"M\u00e9n\u00e9trier-Caux","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3845","article-title":"Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas","volume":"69","author":"Ray-Coquard","year":"2009","journal-title":"Cancer Res"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1093\/icvts\/ivu324","article-title":"Is low serum albumin associated with postoperative complications in patients undergoing oesophagectomy for oesophageal Malignancies","volume":"20","author":"Goh","year":"2015","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt247","article-title":"A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer","volume":"24","author":"Kadalayil","year":"2013","journal-title":"Ann Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00571-6","article-title":"Neutrophils in cancer: heterogeneous and multifaceted","volume":"22","author":"Hedrick","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","article-title":"Neutrophil diversity and plasticity in tumour progression and therapy","volume":"20","author":"Jaillon","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0222-4","article-title":"Tumour-associated neutrophils in patients with cancer","volume":"16","author":"Shaul","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.122.321861","article-title":"Mechanism of tumor-platelet communications in cancer","volume":"132","author":"Dudiki","year":"2023","journal-title":"Circ Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41568-023-00639-6","article-title":"The dynamic role of platelets in cancer progression and their therapeutic implications","volume":"24","author":"Li","year":"2024","journal-title":"Nat Rev Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1663268\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T06:17:22Z","timestamp":1763619442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1663268\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2025.1663268"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1663268","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"article-number":"1663268"}}